TargetMol

Suriclone

Product Code:
 
TAR-T28887
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28887-1mg1mg£188.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28887-5mg5mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28887-10mg10mg£496.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28887-25mg25mg£760.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28887-50mg50mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28887-100mg100mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Suriclone is an anxiolytic drug belonging to the family of cyclopyrrolones. Suriclone has a very similar pharmacological profile to the benzodiazepine family of drugs including sedative and anxiolytic properties but with less amnestic effects. The mechanism of action by which suriclone produces its sedative and anxiolytic effects is by modulating GABA-A receptors, although suriclone is more subtype-selective than most benzodiazepines.
CAS:
53813-83-5
Formula:
C20H20ClN5O3S2
Molecular Weight:
477.98
Pathway:
Membrane transporter/Ion channel|Neuroscience
Purity:
0.98
SMILES:
CN1CCN(CC1)C(=O)OC1N(C(=O)C2=C1SCCS2)c1ccc2ccc(Cl)nc2n1
Target:
GABA Receptor

References

1. Morishita H, Kushiku K, Matsuki J, Tokunaga T, Inoue T, Mori R, Kawamoto H, Furukawa T. Pharmacological effects of the antianxiety compound suriclone and its principal metabolites. Arzneimittelforschung. 1987 Dec;37(12):1332-40. PubMed PMID: 2896505. 2. Ono H, Morishita S, Kasuya M, Kobayashi M, Miyamoto M, Oka J, Goto M, Fukuda H. Comparison of the effects of the new anxiolytic suriclone and benzodiazepines on motor function and electroencephalogram. Arzneimittelforschung. 1987 Apr;37(4):384-8. PubMed PMID: 2886128. 3. Semlitsch HV, Anderer P, Saletu B. Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects. Eur J Clin Pharmacol. 1995;49(3):183-91. PubMed PMID: 8665994. 4. Perault MC, Chapelle G, Bouquet S, Chevalier P, Montay G, Gaillot J, Chakroun H, Guillet P, Vandel B. Pharmacokinetic and pharmacodynamic study of suriclone imipramine interaction in man. Fundam Clin Pharmacol. 1994;8(3):251-5. PubMed PMID: 7927120.